Načítá se...
Diffuse large B-cell lymphoma: new targets and novel therapies
Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalidomide. Three CAR-T cell prod...
Uloženo v:
| Vydáno v: | Blood Cancer J |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group UK
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8021545/ https://ncbi.nlm.nih.gov/pubmed/33820908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00456-w |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|